225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks. (June 2020)

• Record Type: Journal Article
• Authors: Vatsa, Rakhee; Sood, Ashwani; Vadi, Shelvin Kumar; Das, Chandan Krushna; Kaur, Komalpreet; Parmar, Madan; Mittal, Bhagwant Rai
• Is Part Of: Clinical nuclear medicine. Volume 45:Number 6(2020)
• Publication Date: 2020-06
• Subjects: metastatic castrate-resistant prostate cancer -- 68Ga-PSMA-11 -- PET/CT -- 225Ac-PSMA-617 -- photopeaks; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003031
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: PSMA-based radioligand therapies have shown the beneficial effect in metastatic castrate-resistant prostate cancer (mCRPC) patients when they become refectory to the established treatments with associated potential toxicities and high mortality rate. 225 Ac-PSMA therapy is known to be remarkably effective in substantially pretreated mCRPC patients. However, posttherapy imaging is usually not performed as alpha emitters are really difficult to image. We presents a patient of mCRPC treated with 225 Ac-PSMA-617, and his posttherapy whole-body scans acquired by using 3 different photopeaks (78, 218, and 440 keV) fairly demonstrated the tracer's distribution and the efficacy of targeted alpha therapy.